EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off Assembly Line

EPGL Seeing High Demand Beginning for First New Medical Device Released in US and International Markets

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Irvine, CA (PRWEB) March 21, 2013

EP Global Communications, Inc. (the Company), (Pink Sheets: EPGL.PK) is pleased to announce that the Company has begun selling MPDD units both in the US Market and Internationally. The exclusive Singapore distributor has secured the first 1,000 units to come off the assembly line. In addition, the Company is simultaneously engaging the top 20 international markets throughout the world in addition to the United States. "We are aggressively going after all the markets now as of today". Said David T. Markus Ph.D. Vice President of BioMems development. "Shareholders will soon learn our innovative new business model strategy for VIP physicians everywhere. We have taken a page from the Apple / Google marketing playbook. We will be a different kind of medical device company."

About EP Global Communications, Inc.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.

Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


Contact

  • Brady Peterson
    EP Global Communications, Inc.
    877-287-6175
    Email
Follow us on: Contact's Twitter